Search Results: All recruiting trials found

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

27 trials found

Drug	NCT#	Name	Phase [desc]
DCC-3116 + Ripretinib	NCT05957367	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	1/2

neoBOMB1	NCT03872778	[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)	1/2

Regorafenib + Avelumab	NCT03475953	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)	1/2

Bezuclastinib plus Sunitinib	NCT05208047	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors	3

Famitinib	NCT04409223	Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib	3

Ripretinib	NCT05734105	A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)	3

Avelumab + Axitinib	NCT04258956	A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy (AXAGIST)	2

Belzutifan	NCT04924075	Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)	2

Bezuclastinib plus Sunitinib	NCT06208748	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	2

ctDNA plus Sunitinib or Regorafenib	NCT05366816	ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST	2

Imatinib	NCT05009927	Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)	2

Imatinib	NCT05493215	Imatinib TDM (Therapeutic Drug Monitoring) in GIST	2

Imatinib	NCT04933669	Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01)	2

Imatinib	NCT05385549	5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk	2

Imatinib + Atezolizumab	NCT05152472	A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)	2

Lenvatinib	NCT04193553	Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (LENVAGIST)	2

Paclltaxel	NCT03944304	Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.	2

Regorafenib	NCT06087263	Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.	2

HQP1351	NCT03594422	A Study of HQP1351 in Patients With GIST or Other Solid Tumors	1

IDRX-42	NCT05489237	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	1

INBRX-109 + Temozolomide	NCT03715933	Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas	1

NB003	NCT04936178	A Study of NB003 in Patients With Advanced Malignancies	1

Pimitesib	NCT05245968	A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)	1

Apatinib Mesylate	NCT05751733	Apatinib Mesylate (Rivoceranib) Versus Standard Second-line TKI in the Treatment of Advanced GIST

Imatinib + Sunitinib + Regorafenib	NCT02331914	GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

Ripretinib	NCT05132738	Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy

Surgery	NCT04557969	Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Search Results: All recruiting trials found

27 trials found

Drug

NCT#

Name

Phase [desc]